China Journal of Leprosy and Skin Diseases ›› 2021, Vol. 37 ›› Issue (3): 157-159.doi: 10.12144/zgmfskin202103157

• Articles • Previous Articles     Next Articles

Assessment of the efficacy of Secukinumab in the treatment of six cases of childhood psoriasis

XIE Hui1, NIU Meili2, WANG Xinhui1, LIU Qu1, MIAO Guoying2   

  1. 1 Clinical Medical Collefe of Hebei University of Engineering, Handan 056000, China; 
    2 Affiliated Hospital of Hebei  Engineering University, Handan 056000, China
  • Online:2021-03-15 Published:2021-03-03
  • Contact: MIAO Guoying, E-mail: guoyingmiao@163.com

PDF (PC)

296

Like

Abstract: Objective: To evaluate the clinical efficacy and safety of Secukinumab in the treatment of childhood psoriasis. Methods: The children with psoriasis who failed to respond to conventional treatments were given subcutaneous secukinumab 150 mg at week 0,1,2,3 and 4. The psoriasis area severity index (PASI) and body surface area (BSA) were assessed. Results: At week 4 of the treatment, all the 6 patients achieved PASI 90, and BSA significantly decreased, with no adverse reaction. Conclusion: Secukinumab is effective and safe for childhood psoriasis.

Key words: psoriasis in children, Secukinumab